Cigna Group (NYSE:CI) Given Average Recommendation of “Moderate Buy” by Brokerages

Cigna Group (NYSE:CI) has received an average recommendation of “Moderate Buy” from the twenty-two ratings firms that are presently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $333.1053.

A number of equities analysts have recently weighed in on CI shares. Mizuho set a $325.00 price objective on Cigna Group in a research note on Friday, January 9th. Robert W. Baird decreased their price target on shares of Cigna Group from $372.00 to $315.00 and set an “outperform” rating for the company in a research note on Thursday, December 11th. Barclays reduced their target price on shares of Cigna Group from $305.00 to $303.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Royal Bank Of Canada decreased their price objective on shares of Cigna Group from $344.00 to $333.00 and set an “outperform” rating for the company in a research report on Friday, February 6th. Finally, Wall Street Zen raised shares of Cigna Group from a “hold” rating to a “buy” rating in a report on Saturday, February 7th.

Insider Buying and Selling

In other news, insider Nicole S. Jones sold 2,307 shares of Cigna Group stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $288.91, for a total transaction of $666,515.37. Following the completion of the transaction, the insider owned 32,647 shares of the company’s stock, valued at $9,432,044.77. The trade was a 6.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Everett Neville sold 1,719 shares of Cigna Group stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $288.91, for a total transaction of $496,636.29. Following the completion of the transaction, the insider owned 5,670 shares in the company, valued at approximately $1,638,119.70. This trade represents a 23.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Harbor Capital Advisors Inc. raised its position in shares of Cigna Group by 119.5% during the third quarter. Harbor Capital Advisors Inc. now owns 90 shares of the health services provider’s stock worth $26,000 after purchasing an additional 49 shares during the period. Wilkerson Advisory Group LLC acquired a new position in shares of Cigna Group in the fourth quarter valued at $25,000. Beacon Financial Strategies CORP bought a new position in shares of Cigna Group during the 4th quarter worth about $28,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Cigna Group during the 4th quarter worth about $29,000. Finally, Prosperity Bancshares Inc acquired a new stake in shares of Cigna Group in the fourth quarter valued at $29,000. Institutional investors own 86.99% of the company’s stock.

More Cigna Group News

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Sanford C. Bernstein upgraded Cigna to “outperform” and raised its price target to $358, citing PBM reform as a clearing event and improved outlook for Evernorth — a catalyst for multiple analysts to raise estimates. Bernstein upgrades CVS and Cigna, citing PBM reform as key clearing event
• Positive Sentiment: Zacks notes CI trades below the industry P/E and highlights Evernorth growth, steady earnings beats and buybacks as supports for the investment case — a valuation/earnings combo that helps explain buying interest. Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now?
• Neutral Sentiment: A valuation review highlights recent share-price weakness versus the specialty-pharmacy growth narrative — useful context for investors weighing whether current discounts already reflect execution risks. Evaluating Cigna Group (CI) Valuation After Recent Share Price Weakness And Specialty Pharmacy Growth Narrative
• Neutral Sentiment: A head-to-head comparison with CVS frames Cigna as the play for stronger earnings quality and capital discipline, while reminding long-term investors to consider income, stability and valuation differences when choosing exposure. CVS vs Cigna: Which Healthcare Giant Belongs in Your Retirement Portfolio?
• Neutral Sentiment: Zacks’ broader industry outlook continues to single out major HMOs (including Cigna) as key players in a sector balancing tech-enabled growth and policy/operational headwinds. Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana and Centene
• Negative Sentiment: Barclays and commentators warn that the timing of a CEO change could surprise investors and introduce strategic/operational uncertainty during a critical execution window. Management transition risk may weigh on sentiment until plans are clearer. The Cigna Group (CI) CEO Change Timing May Come As Surprise to Some Investors, According to Barclays
• Negative Sentiment: Industry pieces flag escalating medical costs, nursing shortages and margin pressure as sector-wide risks that could blunt near-term earnings leverage for HMOs, including Cigna. 4 HMO Stocks to Watch Despite Escalating Costs, Nursing Shortage

Cigna Group Price Performance

Cigna Group stock opened at $267.15 on Friday. The firm has a market capitalization of $70.40 billion, a P/E ratio of 12.04, a PEG ratio of 0.92 and a beta of 0.27. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.74 and a quick ratio of 0.74. The business has a fifty day moving average price of $279.60 and a 200-day moving average price of $282.94. Cigna Group has a one year low of $239.51 and a one year high of $350.00.

Cigna Group (NYSE:CI) last announced its quarterly earnings data on Thursday, February 5th. The health services provider reported $8.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.88 by $0.20. Cigna Group had a net margin of 2.17% and a return on equity of 19.46%. The company had revenue of $72.50 billion during the quarter, compared to analysts’ expectations of $69.53 billion. During the same quarter in the prior year, the company earned $6.64 EPS. The firm’s revenue was up 10.4% on a year-over-year basis. Cigna Group has set its FY 2026 guidance at 30.250- EPS. As a group, equities research analysts forecast that Cigna Group will post 29.77 EPS for the current year.

Cigna Group Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Thursday, March 5th will be given a $1.56 dividend. The ex-dividend date of this dividend is Thursday, March 5th. This is an increase from Cigna Group’s previous quarterly dividend of $1.51. This represents a $6.24 dividend on an annualized basis and a yield of 2.3%. Cigna Group’s dividend payout ratio is currently 28.13%.

Cigna Group Company Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.